Clinical characteristics of patients with relapsed multiple myeloma

Meletios A Dimopoulos; Evangelos Terpos; Rubén Niesvizky; Antonio Palumbo

doi:10.1016/j.ctrv.2015.07.005

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Chapter in a book2017

Treatment of Relapsed/Refractory Patients with Multiple Myeloma

Jacob P. Laubach, Philippe Moreau, Meletios A Dimopoulos, Paul G. Richardson

Article2022

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Meletios A Dimopoulos, Paul G. Richardson, Sagar Lonial

Article2013

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

Roman Hájek, David S. Siegel, Robert Z. Orlowski, Heinz Ludwig, Antonio Palumbo, Meletios A Dimopoulos

Article2018

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

Xiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, Chad C. Bjorklund, Fadi Towfic, Erin Flynt, Katja Weisel, Enrique M. Ocio, Xin Yu, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Philippe Moreau, Anjan Thakurta

Article2020

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios A Dimopoulos, Sara Galimberti, P. Anttila, Marcelo Capra, Michèle Cavo, Craig E. Cole, Cristina Gasparetto, Vânia Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yañez Ruiz, Jian Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij